Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition.
about
Proteomic analysis of multiple myeloma: current status and future perspectives.Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma.Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activitiesGlobal proteomic assessment of the classical protein-tyrosine phosphatome and "Redoxome"Comparison of three quantitative phosphoproteomic strategies to study receptor tyrosine kinase signaling.Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma.Differential regulation of FGFR3 by PTPN1 and PTPN2.Proteomic analysis in multiple myeloma research.Proteomic profiles of human lung adeno and squamous cell carcinoma using super-SILAC and label-free quantification approaches.Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.FGF and ERK signaling coordinately regulate mineralization-related genes and play essential roles in osteocyte differentiation.LMP1 signaling pathway activates IRF4 in latent EBV infection and a positive circuit between PI3K and Src is required.Tyrosine phosphorylation of the Lyn Src homology 2 (SH2) domain modulates its binding affinity and specificity.Interferon regulatory factor 4 is activated through c-Src-mediated tyrosine phosphorylation in virus-transformed cells.Selecting Sample Preparation Workflows for Mass Spectrometry-Based Proteomic and Phosphoproteomic Analysis of Patient Samples with Acute Myeloid LeukemiaTyrosine phosphorylation of the Gα-interacting protein GIV promotes activation of phosphoinositide 3-kinase during cell migration.Retroviral retention activates a Syk-dependent HemITAM in human tetherin.Peripherally derived FGF21 promotes remyelination in the central nervous system.Protein-phosphotyrosine proteome profiling by superbinder-SH2 domain affinity purification mass spectrometry, sSH2-AP-MS.
P2860
Q33807327-68741CA8-1307-4A91-A39B-EC4FA85532DBQ33846310-1B095D4A-3CDB-4085-9524-848920CCDEF8Q34426491-02D2BF6A-3797-4696-8E90-AC95804F417EQ35222996-9F63EFC6-958D-4AB1-B209-5C4AF73E2C01Q35588202-00E4DA83-1682-4E13-979C-95FACB3852EBQ36711842-822124DE-E844-403D-AAFF-D0F1AC1064C6Q37274802-26B93D8E-5375-4C23-87C2-6443C9D47197Q37781730-7D6D971E-C9D2-4E72-9C44-4ADB92648D25Q38437389-F0218233-5939-44B2-A9F4-5E15B185E432Q38671390-A374876B-B139-4DE6-B8C5-AC54F8ECF7D1Q38689573-9DE84550-7818-441D-8E37-0085D9B1F81FQ38732564-45C5656E-E65F-41EC-9121-73C5C3976CFEQ38920190-A1C7C7EC-61A8-489A-AA58-AF151FDB7209Q39134387-C9623B27-1C4F-4EE8-8FB2-123A17A54E9DQ39156071-98F9955F-D888-4F32-92B7-656FA1B57B8CQ39466800-079FD245-C4AC-4CA2-B308-0B30F2CC9B29Q41743410-5166238E-AB20-409F-9F2F-7177EC960EF4Q47927815-E4B271A0-4C64-45B8-A869-47D32C848A9DQ51307782-F5628A67-F2A2-4DCC-B0BA-696948DBD28F
P2860
Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Multiple myeloma phosphotyrosi ...... tivation, and drug inhibition.
@en
Multiple myeloma phosphotyrosi ...... tivation, and drug inhibition.
@nl
type
label
Multiple myeloma phosphotyrosi ...... tivation, and drug inhibition.
@en
Multiple myeloma phosphotyrosi ...... tivation, and drug inhibition.
@nl
prefLabel
Multiple myeloma phosphotyrosi ...... tivation, and drug inhibition.
@en
Multiple myeloma phosphotyrosi ...... tivation, and drug inhibition.
@nl
P2093
P2860
P356
P1476
Multiple myeloma phosphotyrosi ...... ctivation, and drug inhibition
@en
P2093
Ana Nikolic
Ian I Stewart
Jiefei Tong
Jonathan R St-Germain
Lily L Jin
Michael F Moran
Moyez Dharsee
Paul Taylor
P2860
P304
20127-20132
P356
10.1073/PNAS.0910957106
P407
P577
2009-11-09T00:00:00Z